World Library  
Flag as Inappropriate
Email this Article

Fenretinide

Article Id: WHEBN0009694808
Reproduction Date:

Title: Fenretinide  
Author: World Heritage Encyclopedia
Language: English
Subject: Isotretinoin, Tretinoin, Retinoids, Carotenoids, Breast cancer
Collection: Anilides, Phenols, Retinoids
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Fenretinide

Fenretinide
Skeletal formula of fenretinide
Space-filling model of the Fenretinide molecule
Names
IUPAC name
15-[(4-hydroxyphenyl)amino]retinal
Identifiers
 Y
ChEMBL  Y
ChemSpider  Y
DrugBank  Y
Jmol-3D images Image
KEGG  Y
MeSH
PubChem
UNII  Y
Properties
C26H33NO2
Molar mass 391.546 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 Y  (: Y/N?)

Fenretinide (4-hydroxy(phenyl)retinamide; 4-HPR) (INN) is a synthetic retinoid derivative. Retinoids are substances related to vitamin A. It has been investigated for potential use in the treatment of cancer, as well as in the treatment of cystic fibrosis,[1] rheumatoid arthritis, acne, psoriasis, and has been found to also slow the production and accumulation of a toxin that leads to vision loss in Stargardt's patients.[2]

In cancer studies, Fenretinide treatment may cause ceramide (a wax-like substance) to build up in tumor cells and is associated with the accumulation of reactive oxygen species (ROS), resulting in cell death through apoptosis and/or necrosis.[3] Fenretinide accumulates preferentially in fatty tissue such as the breast, which may contribute to the effectiveness of fenretinide against breast cancer.[4][5] Phase III clinical trial data has suggested that fenretinide reduces breast cancer relapse in pre-menopausal women.[6] Common side effects associated with fenretinide treatment include skin dryness and night-blindness, which is reversible upon cessation of treatment. Specific types of cancer under investigation include or have included ovarian, prostate, cervical, lung, renal, bladder, breast, glioma, skin, head and neck carcinoma, non-Hodgkin's lymphoma, neuroblastoma, and Ewing's sarcoma.

References

  1. ^ Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, Skinner TA, Vilela RM, Kubow S, Lands LC, Hajduch M, Matouk E, Radzioch D. (2008). "Fenretinide Corrects Newly Found Ceramide Deficiency in Cystic Fibrosis". Am J Respir Cell Mol Biol 38 (1): 47–56.  
  2. ^ Radu, Roxana A., Yun Han, Tam V. Bui, Steven Nusinowitz, Dean Bok, Jay Lichter, Ken Widder, Gabriel H. Travis, and Nathan L. Mata. (2005). "Reductions in Serum Vitamin A Arrest Accumulation of Toxic Retinal Fluorophores: A Potential Therapy for Treatment of Lipofuscin-Based Retinal Diseases.". IOVS 46: 4393–401.  
  3. ^ Wu J, DiPietrantonio A, Hsieh T (2001). "Mechanism of fenretinide (4-HPR)-induced cell death". Apoptosis 6 (5): 377–88.  
  4. ^ Formelli, Franca; Monica Clerici; Tiziana Campa; MAria Gaetana Di Mauro; Andrea Magni; Gustavo Mascotti; Daniele Moglia; Giuseppe De Palo; Alberto Costa; Umberto Veronesi (October 1993). "Five-Year Administration of Fenretinide: Pharmacokinetics and Effects on Plasma Retinol Concentrations". Journal of Clinical Oncology 11 (10): 2036–2042.  
  5. ^ Sabichi, Anita; Manual Modiano, J. Jack Lee, Yei-Mei Peng, Ming-Jing Xu, Hugo Vallar, William Dalton, Scott Lippman (July 2003). "Breast Tissue Accumulation of Retinamides in a Randomized Short-term Study of Fenretinide". Clinical Cancer Research 9 (7): 2400–2405.  
  6. ^ Veronesi, U.; L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. G. Di Mauro, A. Costa, E. Marubini, M. B. Sporn, G. De Palo (May 2006). "Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer". Annals of Oncology 17 (7): 1065–1071.  

External links

  • Numerous references and links to current and past clinical trials and studies of fenretinide can be found at the Journal of Clinical Oncology website


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from Hawaii eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.